The global exosomes market size is estimated to reach USD 794.2 million by 2030, registering to grow at a CAGR of 28.73% from 2025 to 2030 . The major factors driving the market include technological advancements in exosome isolation and analytical procedures, growth in government and non-government initiatives for exosome research, and the increasing prevalence of cancer. For instance, according to the World Health Organization (WHO), in 2020 there were about 10 million deaths due to cancer, making it one of the foremost causes of death worldwide. The industry is anticipated to witness rapid growth, owing to the factors, such as the growing need for the identification of cancer biomarkers, detection of infectious agents, and discovery of treatment options for neurodegenerative & Cardiovascular Diseases (CVDs).
Exosomes released by cells into body fluids display different RNA, protein, and lipid contents in patients with various disease conditions as compared to healthy individuals. Hence, exosomes can be used for the development of diagnostic procedures using biomarker identification. The rising demand for fast, accurate, and minimally invasive diagnostic procedures, thus, represents a promising opportunity for the growth of exosome applications. The COVID-19 pandemic led to the disruption of clinical trials investigating the diagnostic and therapeutic potential of exosomes in 2020. In addition, nationwide lockdown restrictions, disruption of supply chains, and diversion of investments toward COVID-19-related products led to a decrease in the research and development activities involving exosomes.
Despite the adverse impact in 2020, the pandemic has opened up several new prospects for the development of COVID-19 vaccines and treatments with the use of exosomes, which, in turn, is expected to boost industry growth over the coming years. For instance, in March 2021, Cell Guidance Systems, a U.S.-based biotechnology research organization, announced plans for the development of exosome therapeutics for treating COVID-19 disease. Moreover, growth in government and non-government initiatives for exosome research is likely to drive the growth during the study period. For instance, in Jan 2023, Mantra Bio raised funding of USD 9 million to advance the development of its lead-targeted exosome therapeutics program.
Similarly, in February 2021, Evox Therapeutics raised a funding of USD 95.18 million to advance the exosome therapeutics and expand the company’s leading exome platform DeliverEX globally. However, stringent regulations pertaining to the approval and commercialization of exosome products may hamper the growth of the industry over the forecast period. In addition, technical difficulties associated with the implementation of exosomes in various applications may hamper the growth during the study period. Some of the major challenges include the lack of efficient transfection strategies and the need for optimization of purification methods. Such, challenges are anticipated to impede the market growth.
Exosomes released by cells into body fluids display different RNA, protein, and lipid contents in patients with various disease conditions as compared to healthy individuals. Hence, exosomes can be used for the development of diagnostic procedures using biomarker identification. The rising demand for fast, accurate, and minimally invasive diagnostic procedures, thus, represents a promising opportunity for the growth of exosome applications. The COVID-19 pandemic led to the disruption of clinical trials investigating the diagnostic and therapeutic potential of exosomes in 2020. In addition, nationwide lockdown restrictions, disruption of supply chains, and diversion of investments toward COVID-19-related products led to a decrease in the research and development activities involving exosomes.
Despite the adverse impact in 2020, the pandemic has opened up several new prospects for the development of COVID-19 vaccines and treatments with the use of exosomes, which, in turn, is expected to boost industry growth over the coming years. For instance, in March 2021, Cell Guidance Systems, a U.S.-based biotechnology research organization, announced plans for the development of exosome therapeutics for treating COVID-19 disease. Moreover, growth in government and non-government initiatives for exosome research is likely to drive the growth during the study period. For instance, in Jan 2023, Mantra Bio raised funding of USD 9 million to advance the development of its lead-targeted exosome therapeutics program.
Similarly, in February 2021, Evox Therapeutics raised a funding of USD 95.18 million to advance the exosome therapeutics and expand the company’s leading exome platform DeliverEX globally. However, stringent regulations pertaining to the approval and commercialization of exosome products may hamper the growth of the industry over the forecast period. In addition, technical difficulties associated with the implementation of exosomes in various applications may hamper the growth during the study period. Some of the major challenges include the lack of efficient transfection strategies and the need for optimization of purification methods. Such, challenges are anticipated to impede the market growth.
Exosomes Market Report Highlights
- The kits & reagents segment held the largest revenue share in 2024. Isolation of extracellular vesicles can be difficult, non-specific, and a tedious process. Hence, key players are launching innovative kits and reagents to broaden the applications of exosomes, which is fueling the segment growth
- By workflow, the downstream analysis segment accounted for the largest share in 2024. Major players are offering various technologically advanced products for increasing the utility of downstream analyses, which can positively affect the segment growth
- The cancer application segment dominated the market in 2024 due to the broad range of applications of exosomes in cancer diagnosis, prognosis, and treatment
- The pharmaceutical & biotechnology companies end-use led industry in 2023 due to a rise in the R&D activities
- North America was the dominant region in 2024 due to the presence of key players, rising government funding for the detection of new biomarkers, and high incidence of chronic conditions
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Exosomes Market Variables, Trends & Scope
Chapter 4. Exosomes Market: Product & Service Estimates & Trend Analysis
Chapter 5. Exosomes Market: Workflow Estimates & Trend Analysis
Chapter 6. Exosomes Market: Application Estimates & Trend Analysis
Chapter 7. Exosomes Market: End Use Estimates & Trend Analysis
Chapter 8. Exosomes Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Danaher
- Hologic Inc.
- Fujifilm Holdings Corporation
- Lonza
- Miltenyi Biotec
- Bio-Techne Corporation
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Abcam plc
- RoosterBio, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | November 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 177.4 Million |
| Forecasted Market Value ( USD | $ 794.2 Million |
| Compound Annual Growth Rate | 28.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
